HIV p24 antigen (recombinant)

Added to your cart

HIV p24 antigen (recombinant)

Cart subtotal: $0.00

View cart (0) Checkout

#SKU P714-3

$75.71

Price excludes shipping costs.
To view our shipping costs click here.

Not all of our products can be shipped to all countries. If you're experiencing issues, please contact our customer service team.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

HIV-1 p24 is carried in the blood of people infected with HIV.It has been shown that a p24 antigen level of >5 pg/ml is predictive of disease progression with an accuracy comparable to that of CD4 lymphocyte count (<350 lymphocytes/mm3) and HIV-1 RNA viral load >30,000 copies/ml, which are cut-offs used in guidelines for the initiation of antiretroviral therapy.Viral capsid protein p24 plays important roles in HIV pathogenesis. Peptides and small molecule inhibitors targeting p24 have shown to inhibit virus replication in treated cells. The p24 capsid protein plays important roles in both early and late stages of HIV-1 replication cycle. During the virus particle assembly, capsid domains interact with Gag polyprotein that undergoes proteolytic cleavage and transforms the immature particles to mature virions.
0.1mg
P714-3

More information

Attributes

Description

  • Shipping Information
  • Dry Ice
  • Abbreviations
  • HIV p24
  • Specification
  • >96%
  • Recommended Use
  • Research and further manufacturing
  • Storage
  • Below -60°C
  • Buffer
  • 20mM Tris, 100mM NaCl, 5mM DTT, 10% Glycerol pH 7.5
  • Presentation Matrix
  • 20mM Tris, 100mM NaCl, 5mM DTT, 10% Glycerol pH 7.5
  • Purity/grade
  • >96%
  • Source
  • Expressed in E.coli
  • Molecular weight
  • 24kDa
  • Uniprot No.
  • Q9WMV8

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox